It is well established that aberrant activation of this pathway is a core driver of CRC development, resulting in the movement of β-catenin into the nucleus and the subsequent activation of target genes including c-MYC [40,41,42], and this activation promotes tumor proliferation and metabolic reprogramming. This evidence concerns the gene MYC and neoplasm.